Takeda Pharmaceutical Company Limited (TKDA) — Capital Reinvestment Ratio
Takeda Pharmaceutical Company Limited (TKDA) has a Capital Reinvestment Ratio of 0.60x as of December 2025, meaning it reinvests 1% of its operating cash flow (€373.25 Billion) in capital expenditures (€222.37 Billion). See TKDA net asset quality index to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Takeda Pharmaceutical Company Limited Capital Reinvestment Ratio (2017–2025)
This chart tracks Takeda Pharmaceutical Company Limited's Capital Reinvestment Ratio across 9 annual periods. Check TKDA capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Takeda Pharmaceutical Company Limited (2017–2025)
Year-by-year Capital Reinvestment Ratio for Takeda Pharmaceutical Company Limited from 2017 to 2025. For live market cap and broader valuation context, see TKDA stock market capitalisation.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.36x | €1.06 Trillion | €379.62 Billion | ▼ -46.5% |
| 2024 | 0.67x | €716.34 Billion | €480.73 Billion | ▲ +3.5% |
| 2023 | 0.65x | €977.16 Billion | €633.69 Billion | ▲ +490.9% |
| 2022 | 0.11x | €1.12 Trillion | €123.25 Billion | ▼ -0.2% |
| 2021 | 0.11x | €1.01 Trillion | €111.21 Billion | ▼ -42.0% |
| 2020 | 0.19x | €669.75 Billion | €127.08 Billion | ▼ -19.8% |
| 2019 | 0.24x | €328.48 Billion | €77.68 Billion | ▲ +33.4% |
| 2018 | 0.18x | €377.85 Billion | €67.00 Billion | ▼ -24.8% |
| 2017 | 0.24x | €261.36 Billion | €61.66 Billion | — |